Introduction
Subarachnoid haemorrhage
Initial severity and prognosis of subarachnoid haemorrhage
Dosage | Initial severity | GOS | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Biomarker | CSF | Plasma | GCS | WFNS | HH | Fisher | 3 months | 6 months | 12 months | Mortality |
ET-1 | + | + | + (CSF) | + (plasma) | ||||||
TNF-α | + | + | – CSF) | – (CSF) | ||||||
IL-6 | + | – | + | |||||||
IL-1β | + | – | – | |||||||
ICAM-1, VCAM-1 | + | + | – (CSF, plasma) | – (CSF, plasma) | – (CSF, plasma) | |||||
Light-chain NF | + | + | ||||||||
Heavy-chain NF | + | + | + | + | ||||||
ApoE | + | + | – | + | ||||||
S100β | + | + | – (CSF) | + (plasma) | + (plasma) | – (CSF) | + (plasma) | |||
ANP | + | + (plasma) | + (plasma) | |||||||
BNP | + | + | + | |||||||
cTnI | + | + | + | + | + | + | ||||
vWF, MMP-9, VEGF | + | + | ||||||||
CRP | + | + | + (CSF, plasma) | + (CSF, plasma) | + (CSF, plasma) | + (CSF, plasma) |